Immunic AG – Home

Immunic is the specialist for selective oral drugs in immunology. As a clinical stage company, we deliver clinical proof-of-concept for best-in-class therapies of chronic inflammatory and autoimmune diseases.


Immunic AG is based in the Munich biotech hub Martinsried and currently develops three products for the treatment of chronic inflammatory diseases including e.g. IBD and psoriasis. IMU-838 will be tested in a phase IIb trial in patients suffering from ulcerative colitis beginning of 2018. IMU-366 is a best-in-class inverse agonist of the nuclear receptor ROR gamma-t and currently in advanced preclinical stage.

Immunic enters into a global option and license agreement with Daiichi Sankyo

Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease Planegg-Martinsried, Germany, November 5th, 2018 – Immunic AG (Immunic Therapeutics), ...
Read More

Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Colitis

Planegg-Martinsried, Germany, April 26th, 2018 – Immunic AG (Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, today announced that it has started the clinical Phase 2 ...
Read More

FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis

Planegg-Martinsried, Germany, January 11th, 2017 – Immunic AG (Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, today announced that it has received communication from the US ...
Read More